Vistagen Therapeutics (VTGN) News Today $2.61 -0.06 (-2.25%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest UpdateVistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decrease of 18.1% from the October 15th total of 644,700 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the shares of the company are sold short.November 15, 2024 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call TranscriptNovember 11, 2024 | insidermonkey.comResearch Analysts Set Expectations for VTGN Q1 EarningsVistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for Vistagen Therapeutics in a report released on Thursday, November 7th. William Blair analyst M. Minter expects that the company will post earnNovember 11, 2024 | marketbeat.comVistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comVistaGen Therapeutics’ Promising Clinical Progress and Strong Financial Position Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comVistagen Therapeutics Reports Increased R&D ExpensesNovember 8, 2024 | markets.businessinsider.comVistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...November 8, 2024 | finance.yahoo.comQ2 2025 Vistagen Therapeutics Inc Earnings Call TranscriptNovember 8, 2024 | gurufocus.comVistagen Therapeutics (VTGN) Scheduled to Post Earnings on ThursdayVistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024November 1, 2024 | businesswire.comVistagen Therapeutics (NASDAQ:VTGN) Stock, Option ChainOctober 30, 2024 | benzinga.comVistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesOctober 10, 2024 | finance.yahoo.comGreat Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Great Point Partners LLC lowered its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 17.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,529,338 shares of the company's stock after selling 329,397 shares during the perSeptember 24, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Stock, Earnings Estimates, EPS, And RevenueSeptember 11, 2024 | benzinga.comCompanies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In GrowthSeptember 6, 2024 | finance.yahoo.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50 Day Moving Average of $3.52September 3, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above Fifty Day Moving Average of $3.49August 24, 2024 | marketbeat.comQ2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN)Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Stock analysts at William Blair increased their Q2 2025 earnings per share estimates for Vistagen Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. William Blair analyst T. Lugo now expects that tAugust 16, 2024 | marketbeat.comBuy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical TrialsAugust 16, 2024 | markets.businessinsider.comBioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate ReportAugust 14, 2024 | msn.comVistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comVTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025August 13, 2024 | markets.businessinsider.comHere's what to expect from VistaGen Therapeutics's earningsAugust 13, 2024 | markets.businessinsider.comVistaGen Therapeutics Q1 2025 Earnings PreviewAugust 13, 2024 | msn.comVistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on TuesdayVistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings after the market closes on Tuesday, August 13, Zacks reports.August 7, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50-Day Moving Average of $3.60Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50-Day Moving Average of $3.60August 6, 2024 | marketbeat.com3 Stocks Under $15 That Could Make You a MillionaireJuly 26, 2024 | investorplace.comEquities Analysts Offer Predictions for Vistagen Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:VTGN)Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Equities research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of Vistagen Therapeutics in a research note issued to investors on Wednesday, June 12th. William Blair analyst T. Lugo now antiJune 14, 2024 | marketbeat.comGreat Point Partners LLC Purchases New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Great Point Partners LLC acquired a new stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,858,735 shares of the company's stock, valued at approximately $9,554,000. Vistagen TheraJune 13, 2024 | marketbeat.comQ4 2024 Vistagen Therapeutics Inc Earnings Call TranscriptJune 12, 2024 | gurufocus.comVistagen Therapeutics Inc (VTGN) Q4 2024 Earnings Call Transcript Highlights: Significant ...June 12, 2024 | gurufocus.comADAR1 Capital Management LLC Takes Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)ADAR1 Capital Management LLC acquired a new position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 245,502 shares of the company's stock, valued at approximately $1,262,000. ADJune 12, 2024 | marketbeat.comVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateJune 11, 2024 | businesswire.comVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024June 7, 2024 | businesswire.comArmistice Capital LLC Takes $2.46 Million Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Armistice Capital LLC bought a new stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 478,000 shares of the company's stJune 6, 2024 | marketbeat.comVistagen to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | businesswire.comVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceMay 23, 2024 | businesswire.com3 Must-Have Penny Stocks to Boost Your 2024 PortfolioMay 14, 2024 | investorplace.comMeme Stock Rebound: 3 Reddit Favorites Primed for a ResurgenceMay 13, 2024 | investorplace.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50-Day Moving Average of $4.69Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50 Day Moving Average of $4.69May 8, 2024 | marketbeat.comVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | businesswire.comAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)April 27, 2024 | markets.businessinsider.comVistagen reports positive results for mental fatigue treatmentApril 26, 2024 | msn.comVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueApril 25, 2024 | businesswire.comVistagen Therapeutics: A Pipeline With Potential In Anxiety And DepressionApril 24, 2024 | seekingalpha.com7 Stocks Under $15 Predicted to Boom in the Next 2 YearsApril 19, 2024 | investorplace.comMillionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027April 9, 2024 | investorplace.comVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceApril 9, 2024 | businesswire.comVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2April 1, 2024 | finance.yahoo.comSecret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027March 31, 2024 | investorplace.com Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! VTGN Media Mentions By Week VTGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼1.750.45▲Average Medical News Sentiment VTGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼11▲VTGN Articles Average Week Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MACK News RZLT News LYEL News ITOS News CCCC News IMMP News ACRS News QURE News LFCR News MRSN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
